March 2025: 3.0 Tobacco—a leading preventable cause of death and disease
March 2025: 3.38 Quantifying the role of tobacco control in averting disease and early death
March 2025: 3.30 Burden of death and disease attributable to tobacco use in Australia
March 2025: 9A.6 Lesbian, gay, bisexual, trans, queer and intersex (LGBTQI+) people
March 2025: 18.3 Prevalence of e-cigarette use
March 2025: 10A.7 Mechanisms of influence—political lobbying
March 2025: 7.21 Lung cancer screening and biomedical risk assessments
February 2025: 13.6 What tobacco taxes apply in Australia?
February 2025: 2.5 Industry sales figures as estimates for consumption
February 2025: 7.9 Increasing smoking cessation at the population level
February 2025: 9.5 Smoking and intergenerational poverty
February 2025: 3.9 Increased susceptibility to infection in smokers
February 2025: 7.2 Quitting intentions, attempts and success among people who smoke
February 2025: 10.13 Industry efforts to discourage smoking?
February 2025: 15.2 Public opinion about smokefree environments
February 2025: 13A.1 Why is it important to address illicit tobacco trade?
February 2025: 13A.5 Estimates of illicit cigarette trade in Australia
February 2025: 13A.8 What has been done in Australia to reduce avoidance and evasion of tobacco taxes?
February 2025: 13A.9 Measures to further strengthen the current regulatory settings to address illicit tobacco trade in Australia
February 2025: 3.5 Other cancers
January 2025: 9A.2 Culturally and linguistically diverse groups
January 2025: 4.19 Public attitudes to secondhand smoke
January 2025: 18.2 Advertising and promotion of e-cigarettes
January 2025: 13.13 Best practice recommendations and future directions for tobacco price and tax policy
January 2025: 13.8 The impact of price increases on tobacco use in Australia
January 2025: 13.9 How do tobacco prices, affordability, taxes, and tax revenue in Australia compare to overseas?
January 2025: 10.19 The future of the tobacco industry
January 2025: 7.11 Smoking cessation and pregnancy
January 2025: 1.13 Smoking by Australian states and territories
January 2025: 1.6 Prevalence of smoking—teenagers
January 2025: 1.12 Prevalence of use of types of tobacco products among people who smoke
December 2024: 13.7 Revenue from tobacco taxes in Australia
December 2024: InDepth 11B Licensing of tobacco sellers
December 2024: 1.5 Prevalence of smoking—middle-aged and older adults
December 2024: 3.29 Smoking and body weight
December 2024: 1.9 Prevalence of tobacco use among Aboriginal and Torres Strait Islander peoples
December 2024: 8.3 Prevalence of tobacco use among Aboriginal and Torres Strait Islander peoples
December 2024: 8.4 Smoking among Aboriginal and Torres Strait Islander children and teenagers
December 2024: 1.3 Prevalence of smoking—adults
December 2024: 18C.4 Chemicals in oral nicotine products
December 2024: 19.0 The global response to the global tobacco epidemic
December 2024: 19.1 Integration of the WHO FCTC into broader global agendas
December 2024: 19.2 WHO FCTC governance framework
December 2024: 19.8 Implementation, compliance and enforcement of the WHO FCTC
December 2024: 19.9 Impact of the WHO FCTC and its influence on other bodies of law
December 2024: 19.10 Implications of the WHO FCTC for Australia
December 2024: 19.11 WHO FCTC in an Australian context: Case study example of Australia’s tobacco plain packaging measures
December 2024: 19.12 WHO FCTC in an Australian context: Case study example of guidance on interacting with the tobacco industry
December 2024: 13.10 Arguments against tax increases
December 2024: 1.4 Prevalence of smoking—young adults
December 2024: 1.2 Overview of major Australian data sets
December 2024: 18.13 Legal status in Australia
November 2024: 4.5 Prevalence of exposure to secondhand smoke in the home
November 2024: 9.9 Are there inequalities in access to and use of treatment for dependence on tobacco-delivered nicotine?
November 2024: 9.3 Contribution of smoking to health inequality
November 2024: 9.2 Trends over time in smoking among priority populations in Australia
November 2024: 10.7 Market share and brand share in Australia
November 2024: Appendix 1 National, State and Territory Contacts
November 2024: 3.34 Public perceptions of tobacco as a drug, and knowledge and beliefs about the health consequences of smoking
October 2024: 9.1 Smoking prevalence and exposure to secondhand smoke among priority populations in Australia
October 2024: Appendix 2 Forward-looking (“endgame”) measures in tobacco control
October 2024: InDepth 13A Avoidance and evasion of taxes on tobacco products
October 2024: 13.12 Public opinion among Australians about tobacco taxes
October 2024: 13.11 The impact of tobacco tax increases on socioeconomically disadvantaged populations
October 2024: 13.5 How affordable are cigarettes in Australia?
October 2024: 13.4 Factors that influence the price of tobacco products in Australia
October 2024: 13.3 How much do tobacco products cost in Australia?
September 2024: 7.16 Pharmacotherapies for smoking cessation
August 2024: 18.6.10 E-cigarette use and mental health
July 2024: 18.6.3 E-cigarette use and cardiovascular disease
July 2024: 7.17 Incentives and rewards for quitting
July 2024: Appendix 16.1 McCabe v British American Tobacco and its aftermath
June 2024: 18.6.5 E-cigarette use and the risk of non-infectious respiratory diseases
June 2024: 18.14 International regulatory overview
June 2024: 18.15 Position of Australian and international public health groups on e-cigarettes, health, and options for regulation
June 2024: 18.7 Effects of e-cigarette use on smoking
May 2024: 18B.1 Types of heated tobacco products
May 2024: 18B.2 The heated tobacco product market
May 2024: 18B.3 Advertising and promotion of heated tobacco products
May 2024: 18B.4 Awareness, perceptions, and use of heated tobacco products
January 1900: 18B.5 Exposure to chemicals from heated tobacco products
May 2024: 18B.6 Health effects of heated tobacco products
May 2024: 18B.7 Effects of heated tobacco product use on smoking
May 2024: 18B.8 Public health and regulatory considerations
May 2024: 18B.10 International regulatory overview
May 2024: 18B.11 Key Australian and international position statements on heated tobacco products
May 2024: 18B.9 Legal status in Australia
May 2024: 18B.0 Introduction
May 2024: 18.11 Cessation interventions to help people quit vaping
May 2024: 18.6.2 Health effects of e-cigarette use during adolescence
May 2024: 2.3 Self-reported measures of tobacco consumption
March 2024: 18.9 Influences on the uptake of e-cigarettes
March 2024: A1.16 Public perceptions of tobacco as a drug, and public opinion regarding tobacco control policies
February 2024: InDepth 18C: Nicotine pouches and other non-therapeutic oral nicotine products
February 2024: 18C.1 Oral nicotine products and the oral nicotine market
February 2024: 18C.2 Advertising and promotion of oral nicotine products
February 2024: 18C.3 Awareness, perceptions and use of oral nicotine products
February 2024: 18C.5 Health effects of oral nicotine products
February 2024: 18C.6 Public health and regulatory considerations
February 2024: 18C.7 Legal status of oral nicotine products in Australia
February 2024: 18C.8 International regulatory overview
February 2024: 1.7 Trends in the prevalence of smoking by socio-economic status
February 2024: 3.18 Other conditions with possible links to smoking
February 2024: 3.17 Inflammatory conditions and autoimmune disease
January 2024: 9A.4 People experiencing homelessness
November 2023: 9A.5 People experiencing incarceration
November 2023: 3.4 Lung cancer
October 2023: 12.6 Additives and flavourings in tobacco products
October 2023: 12.6.1 Why are chemicals added to tobacco products?
October 2023: 12.6.2 Additives that increase the addictiveness of tobacco products
October 2023: 12.6.4 Additives that modify the processing, shelf-life and burn rates of tobacco products
October 2023: 12.6.3 Additives that increase the attractiveness of tobacco products
October 2023: 12.6.5 Toxicity of tobacco product additives
October 2023: 12.6.6 Priority additives for reporting in Europe
October 2023: 12.6.7 Additives in Australian cigarettes
October 2023: 12.6.8 Perceptions of additives among the community
October 2024: 12.6.9 Consumer perceptions of flavoured tobacco products
October 2023: 12.6.10 Flavoured tobacco products used by specific groups of people
October 2024: 12.6.11 Effects of flavoured tobacco products on smoking initiation and cessation
October 2023: 12.6.13 Regulation of other additives
October 2023: 12.6.12 Regulation of flavourings and flavoured tobacco products
October 2023: 12.7 Menthol
October 2023: 18.6.4 E-cigarette use and possible cancer risk
August 2023: 18.5 Chemicals in e-liquids and e-cigarette aerosols
August 2023: 18.4 Safety risks and abuse potential of e-cigarettes
August 2023: 3.27 Health effects of smoking tobacco in other forms
July 2023: 7.8 How can relapse be prevented?
July 2023: 18.1 E-cigarette products and the e-cigarette market
May 2023: 6.13 Addiction and the adolescent smoker
May 2023: 8.6 Smoking cessation and Aboriginal and Torres Strait Islander peoples
May 2023: InDepth 12D: Reduced fire risk (RFR) cigarettes
May 2023: 11.9 Retail promotion and access
May 2023: 8.13 Policies for advancing tobacco control programs among Aboriginal and Torres Strait Islander peoples
April 2023: 8.15 The role of health workers and community organisations
April 2023: 11.7 Promotional events
April 2023: 11.8 Trade promotions
April 2023: 11A.6 International flow-on effects
October 2020: 16.3 Litigation by individuals
March 2023: 8.7 Morbidity and mortality caused by smoking among Aboriginal and Torres Strait Islander peoples
March 2023: 5.24 The profound effects of the denormalisation of smoking
March 2023: 2.4 Expenditure on tobacco products
February 2023: 5.30 Harnessing predictors of uptake to prevent smoking
February 2023: 9.0 Introduction
February 2023: 9A.7 Military personnel and veterans
February 2023: 18A.5 Regulating sale and promotion of smokeless tobacco
February 2023: 18.12 Public perceptions of the risks and benefits of e-cigarettes
February 2023: 18.6.9 Exposure to secondhand e-cigarette emissions
January 2023: 18.6.1Health effects of e-cigarette use during pregnancy
January 2023: 18.6.6 E-cigarette use and the risk of infectious diseases
January 2023: 18.6.7 E-cigarette use and oral health
January 2023: 18.6.8 Other health risks
January 2023: 18.6 The health effects of e-cigarette use
January 2023: 18.0 Introduction
January 2023: 5.29 School-based interventions
January 2023: 7.5 What we know about how smokers are persuaded to attempt to quit
January 2023: 7.18 Alternative therapies and emerging treatments
December 2022: 7.13 Cessation assistance: printed self-help materials
November 2022: 3.36 Health effects of occasional (“social”) smoking and cutting down
November 2022: 5.28 Peer-based approaches
November 2022: 9.7 Explanations of socio-economic disparities in smoking
November 2021: 15.7 Legislation to ban smoking in public spaces
October 2022: 5.27 Family and home-based interventions to reduce smoking uptake
September 2022: 5.25 Media campaigns and young people
September 2022: 11A.9 Real-world research on the effects of plain packaging
August 2022: 7.6 How smokers go about quitting
August 2022: 7.19 Interventions tailored for age and/or gender
August 2022: 7.10 Role of health professionals and social services
July 2022: 7.14 Cessation assistance: telephone- and internet-based interventions
July 2022: 7.12 Cessation interventions for people with serious health conditions
July 2022: 1.10 Prevalence of smoking in other high-risk sub-groups of the population
July 2022: 9.4 The relationship between tobacco smoking and financial stress
July 2022: 10.18 The investment of public funds in tobacco - the case for divestment
June 2022: 9.6 Tailored and targeted interventions for low socioeconomic groups
June 2022: 4.16 Secondhand smoke and pregnancy
May 2022: 9A.8 Single parents
May 2022: 9A.3 People with substance use and mental disorders
May 2022: 14.3 Public education campaigns to discourage smoking: the Australian experience
October 2022: 15.6 Smoking bans in the home and car
April 2022: 9A.1 People living in regional and remote areas of Australia
April 2022: 5.16 Smoking in movies, TV and other popular culture/media
April 2022: 5.13 Products and packaging created to appeal to new users
March 2022: 9.8 Are current strategies to discourage smoking in Australia inequitable?
February 2022: 10.14 Ethical issues related to tobacco farming and production
January 2022: 12.0 Introduction
January 2022: 12.1 Tobacco in cigarettes
January 2022: 12.2 Other types of tobacco products
January 2022: 12.3 Chemicals and contaminants in tobacco products
January 2022: 12.4 Emissions from tobacco products
January 2022: 12.5 Measuring emissions and exposure to tobacco products
January 2022: 12.8 Construction of cigarettes and cigarette filters
January 2022: 12.9 Labelling of tobacco products in Australia
January 1900: InDepth 12C: Reducing the nicotine content of cigarettes
January 2022: 18.10 Policies and programs to reduce e-cigarette use among young people and non-smokers
December 2021: 17.2 The costs and benefits of smoking to the Australian economy
October 2021: 16.2 Litigation brought by Australian consumer and regulatory groups against the tobacco industry
October 2021: 10.16 The environmental impact of tobacco use
October 2021: 18.8 Population-level benefits and harms of increasing e-cigarette use
September 2021: 10.15 The environmental impact of tobacco production
August 2021: 16.5 Legal cases initiated by tobacco industry
August 2021: 3.7 Pregnancy and smoking
July 2021: 3.11 Dental diseases
July 2021: 4.10 Cancers of other sites
July 2021: 3.21 Health effects for young people who smoke
July 2021: 3.1 Smoking and cardiovascular disease
June 2021: 3.23 Smoking, dementia and cognition
June 2021: 3.22 Poorer quality of life and loss of function
June 2021: 3.13 Musculoskeletal diseases
June 2021: 3.14 Skin
May 2021: 3.12 Gastro-intestinal diseases
May 2021: 3.8 Child health and maternal smoking before and after birth
April 2021: 2.2 Dutiable tobacco products as an estimate of tobacco consumption
April 2021: 6.8 Interactions between tobacco smoke and medications
April 2021: 11A.5 Major milestones in legal challenges to the legislation
March 2021: 8.14 The effectiveness of population-level tobacco control strategies
March 2021: 8.10 Tobacco action initiatives targeting Aboriginal and Torres Straits Islander peoples
March 2021: 2.0 Introduction
March 2021: 3.28 Health 'benefits' of smoking?
March 2021: 4.17 Health effects of secondhand smoke for infants and children
March 2021: 4.18 Other health effects
March 2021: 4.1 What is secondhand smoke?
February 2021: 3.25 Smoking compared with or in combination with other pollutants
February 2021: 8.5 Types of tobacco used by and levels of consumption among Aboriginal and Torres Strait Islander peoples
February 2021: 8.1 Aboriginal and Torres Strait Islander peoples: social disadvantage, health and smoking—an overview
January 2021: 3.24 Genetic influences on tobacco-caused disease
January 2021: 3.15 The impact of smoking on treatment of disease
December 2020: 3.2 Respiratory diseases (excluding lung cancer)
October 2020: 5.18 Uptake: a concluding note
October 2020: 5.8 The smoking behaviour of peers, and peer attitudes and norms
October 2020: 5.10 Cultural background
September 2020: 5.17 Factors influencing uptake of smoking later in life
September 2020: 5.21 Reducing tobacco access and supply
August 2020: 7.7 Environmental and biopsychosocial factors that influence quitting
August 2020: 7.4 What finally prompts smokers to attempt to quit?
August 2020: 3.32 Health effects of smoking other substances
July 2020: 3.31 Morbidity and mortality due to tobacco-caused disease and socio-economic disadvantage
July 2020: 5.5 Temperament, mental health problems and self-concept
July 2020: 5.0 Introduction
July 2020: 5.6 Intentions, attitudes and beliefs
July 2020: 5.31 Other drug use
July 2020: 5.11 Accessibility of tobacco products to young smokers
July 2020: 5.12 Affordability of tobacco products
July 2020: 10.17 Public attitudes to the tobacco industry
July 2020: 10.5 Retailing of tobacco products in Australia
July 2020: 18A.2 Prevalence of use of smokeless tobacco in Australia
June 2020: 3.16 Smoking and diabetes
May 2020: 3.19 Smoking and accidents
May 2020: 3.3 Smoking and cancer
May 2020: 3.20 Nicotine and carbon monoxide poisoning
May 2020: 3.10 Eye diseases
May 2020: 5.15 Tobacco advertising and promotion targeted at young people
April 2020: 5.14 Smokefree policies
April 2020: 7.15 Individual and group-based cessation assistance
March 2020: 7.1 Health and other benefits of quitting
March 2020: 10.6 Retail value and volume of the Australian tobacco market
February 2020: 3.6 Reproductive health
February 2020: 3.26 Health effects of brands of tobacco products which claim or imply, delivery of lower levels of tar, nicotine and carbon monoxide
January 2020: 17.0 Introduction
January 2020: 17.1 Economic terminology and methods
January 2020: 17.3 The economic rationale for intervention in the tobacco market
January 2020: 17.4 Economic evaluations of tobacco control interventions
January 2020: 17.5 Impact of tobacco control strategies on the Australian economy
January 2020: 17.6 Optimal investment in tobacco control
October 2020: 16.4 Criminal cases against the tobacco industry
December 2019: 5.7 The home environment
November 2019: 14.4 Examining the effectiveness of public education campaigns
November 2019: 14.6 News media coverage
November 2019: 14.1 Mass media public education campaigns: an overview
November 2019: 14.5 Targeting of public education campaigns and different types of media channels
November 2019: 14.2 The role of mass media campaigns within a comprehensive smoking control program
November 2019: 11.11 Internet promotion
October 2019: 12A.7 Public support for health warnings
October 2019: 12A.8 Future directions for warnings
September 2019: 4.7 Estimates of morbidity and mortality attributable to secondhand smoke
August 2019: 5.9 The educational environment: achievements, aspirations and 'school connectedness'
August 2019: 5.4 Adolescence and brain maturation
July 2019: 2.1 Production and trade data as a basis for estimating tobacco consumption
July 2019: 10.3 The manufacturing and wholesaling industry in Australia - major international companies
July 2019: 12A.1 History of health warnings in Australia
July 2019: 12A.0 Introduction and rationale for health warnings
July 2019: 12A.2 Health warnings used in other countries
July 2019: 12A.3 Evidence about the effects of health warnings
July 2019: 12A.4 What makes an effective health warning?
July 2019: 12A.5 What has been the impact of pictorial health warnings in Australia?
July 2019: 12A.6World Health Organization recommendations on health warnings
July 2019: 10.11 Corporate responsibility and the birth of good corporate citizenship
May 2019: 10.0 Introduction
May 2019: 10.4 Other importers operating in the Australian market
May 2019: 10.2 The global tobacco manufacturing industry
February 2019: 5.1 Stages in the uptake of smoking
February 2019: 5.2 Factors influencing uptake by young people: overview
February 2019: 5.3 Early biological factors
January 1900: InDepth 11A Packaging as promotion: Evidence for and effects of plain packaging
November 2018: 11A.0 Introduction
November 2018: 11A.1 Plain packaging as a solution to the misleading and promotional power of packaging
November 2018: 11A.2 Australian announcement of plain packaging legislation
November 2018: 11A.3 Analysis of major industry arguments against plain packaging
November 2018: 11A.4Milestones in adoption of legislation
November 2018: 11A.7 Initial industry responses to attempt to mitigate the impact of legislation
November 2018: 11A.8 Experimental research on the effects of plain packaging
September 2018: 11.4 State and territory legislation
June 2018: 15.9 Effectiveness of smokefree legislation in reducing exposure to tobacco toxins, improving health, and changing smoking behaviours
May 2018: 10A.8 Mechanisms of influence—participation in regulatory review processes
May 2018: 10A.2 The arguments
May 2018: 10A.3 Mechanisms of influence—Industry-funded research
May 2018: 10A.4 Mechanisms of influence—undermining public health organisations
May 2018: 10A.5 Mechanisms of influence—mobilising support from the industry and those with shared aims
May 2018: 10A.6 Mechanisms of influence—media relations
February 2018: 6.12 Measures of tobacco dependence
February 2018: 6.14 Smokers’ attitudes to and beliefs about addiction
January 2018: 6.9 Predictors of nicotine dependence
January 2018: 6.10 Acute effects of nicotine on the body
January 2018: 6.11 Tolerance, dependence and withdrawal
January 2018: 6.1 Defining nicotine as a drug of addiction
January 2018: 6.2 Pharmacokinetics
January 2018: 6.3 Mechanism of action
January 2018: 6.5 Mood effects
January 2018: 6.7 Clinical populations
December 2017: 1.11 Prevalence of smoking among health professionals
November 2017: 10.1 The tobacco growing industry
September 2017: 10.8 Trends in products and packaging
September 2017: 10.9 Brand portfolio strategies in the Australia market
July 2017: 10.12 The tobacco industry's revised stance on health issues
June 2017: 10.10 The tobacco industry exposed: tobacco industry document repositories
January 2017: 4.4 Measuring exposure to secondhand smoke
January 2017: 4.6 Mechanisms of disease
January 2017: 4.3 Thirdhand smoke
January 2017: 4.20 Health effects of secondhand smoke on pets
January 2017: 4.2 What is in secondhand smoke?
January 2017: 4.0 Background
January 2017: 4.8 Cardiovascular disease and secondhand smoke
January 2017: 4.9 Lung cancer and secondhand smoke
January 2017: 4.11 Effects of secondhand smoke on the respiratory system in adults
January 2017: 4.12 Secondhand smoke and increased risk of infectious disease
January 2017: 4.13 Secondhand smoke and type 2 diabetes mellitus
January 2017: 4.14 Secondhand smoke and mental health
January 2017: 4.15 Oral health
January 2017: 15.4 Smoking bans in key public areas and environments
October 2016: 11.3 Commonwealth (national) legislation
October 2016: 7.3 Theories about smoking and quitting
October 2016: 7.20 National policy and progress in encouraging and supporting cessation
August 2016: 3.37 Chemoprevention of tobacco–related disease
August 2016: 8.8 Economic issues relating to tobacco use among Aboriginal and Torres Straits Islander peoples
August 2016: 8.9 Attitudes to and beliefs about smoking among Aboriginal and Torres Strait Islander peoples
August 2016: 8.11 The relationship between tobacco and other drug use in Aboriginal and Torres Strait Islander communities
August 2016: 8.12 The tobacco industry and Indigenous communities
January 1900: InDepth 12B Regulation to disclose or reduce harm from tobacco products
August 2016: 18A.3 Health effects of various forms of smokeless tobacco
August 2016: 18A.4 Snus as a potential harm reduction strategy
October 2024: InDepth 18A Smokeless tobacco
October 2014: 5.20 Approaches to youth smoking prevention
October 2014: 5.22 Taxation and pricing of tobacco products
October 2024: 13.1 Price elasticity of demand for tobacco products
October 2024: 13.2 Theories of demand
April 2012: 5.23 Reducing product appeal
October 2012: 2.9 Estimates of total tobacco consumption in Australia
November 2011: 16.0 Introduction